Non- contrast Enhanced Multiparametric Renal Magnetic Resonance
Non- contrast Enhanced Multiparametric Renal Magnetic Resonance: MRI is performed in a single multiparametric scan session with no need for contrast agents, and to depict changes in tissue microstructure associated with inflammation and fibrosis plus alterations in oxygenation.
Study summary
Chronic kidney disease (CKD) is a global health concern because more than 10% of the world's population have it, its prevalence is increasing, and CKD is an important contributor to morbidity and mortality for this population.
The majority of the people with CKD aren't aware and there are not available tools for early CKD detection and for an accurate prediction on these patients. Many CKD patients exhibit progressive renal dysfunction, demonstrating a failure of current, non-specific therapeutic strategies. Better methods are urgently needed for i) early diagnosis of CKD, and prediction of its progression for improved stratification of patients and better targeting of current treatments; and ii) to directly assess structural and functional responses of the kidney to new therapies and identify those patients who respond.
Over the past decade, renal Magnetic Resonance Imaging (MRI) has emerged as a promising technique for improved understanding and characterisation of renal pathophysiology. Compared to histopathology, MRI is non-invasive and avoids sampling bias by characterising the entire kidney with high spatial resolution.
In spite of a number of single centre studies showing renal MRI feasibility and potential to address a number of key clinical questions, current methodological differences across studies hinder reliable comparisons of the results, which can only be regarded as preliminary. Standardization of acquisition and processing protocols across centres is therefore needed, and this will also lead to the possibility to provide preliminary data of the multiparametric renal MRI clinical validity and utility.
The purpose of this study is to standardize, assess the feasibility and provide preliminary evidence of clinical validity and utility of the multiparametric renal MRI.
To reach this goal two groups of subjects are involved:
* Group 1 (healthy volunteers). In this group the repeatibility and reproducibility of multiparametric renal MRI will be assessed.
* Group 2 (CKD patients). In this group the feasibility, the acceptability, the reproducibility and the preliminary clinical validity of multiparametric renal MRI will be assessed.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
GROUP 1:
1. Provision of written informed consent prior to any study specific procedures
2. Male and female subjects aged more than18 years
3. Normotensive (office Systolic Blood Pressure values \< 140 mmHg and Diastolic Blood Pressure values ≤ 90 mmHg)
4. Normal renal condition for age (established by estimating Glomerular Filtration Rate using CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration, Creatinine Equation)
5. Negative result upon urine dipstick testing for haematuria or proteinuria.
6. Normal Urine Albumin-to-Creatinine Ratio (UACR) (\<30 mg/g)
GROUP 2:
1. Provision of written informed consent prior to any study specific procedures
2. Male and female patients aged more than18 years
3. CKD stage 2 or 3, with albuminuria up to 2000 mg
Exclusion Criteria:
GROUP 1 and 2
1. Previous enrollment in the present study
2. Contraindications to MRI including due to:
* Claustrophobia
* Pregnancy
* Cardiac pacemakers or other MRI-incompatible prostheses
Only GROUP 2:
1. Urine Albumin-to-Creatinine Ratio higher than 2000 mg/g or 24h urine total albumin \>2 g
2. Polycystic kidney disease, renovascular disease, active/current nephrotic syndrome, reflux nephropathy and known congenital renal diseases or solitary kidney.
3. Active malignancy or acute or chronic inflammatory disease, HIV
4. Acute kidney injury, as defined by the the KDIGO guidelines, during the last three months.
5. Need of a new immunosuppressive therapy for treating renal disease relapse in the preceding three months.
6. Dialysis or kidney transplantation
7. CKD stages 4 or 5
8. New medication in the preceding two weeks (diuretic, hypertensive, SGLT2 treatment)
Primary outcome measure(s)
GROUP 1: within subject total kidney volume coefficient of variation in few hour time — At day 0 Within subject coefficient of variation of measures computed by multiparametric renal MRI repeated in few hour time to assess total kidney volume repeatability in the whole group of healthy volunteers
GROUP 1: within subject total kidney volume coefficient of variation after 1-2 weeks — At day 7-14 Within subject coefficient of variation of measures computed by multiparametric renal MRI repeated after 1-2 weeks to assess total kidney volume reproducibility in the whole group of healthy volunteers
GROUP 1: within subject renal artery blood flow coefficient of variation in few hour time — At day 0 Within subject coefficient of variation of measures computed by multiparametric renal MRI repeated in few hour time to assess renal artery blood flow repeatability in the whole group of healthy volunteers
GROUP 1: within subject renal artery blood flow coefficient of variation after 1-2 weeks — At day 7-14 Within subject coefficient of variation of measures computed by multiparametric renal MRI repeated after 1-2 weeks to assess renal artery blood flow reproducibility in the whole group of healthy volunteers
GROUP 1: within subject cortical perfusion coefficient of variation in few hour time — At day 0 Within subject coefficient of variation of measures computed by multiparametric renal MRI repeated in few hour time to assess cortical perfusion repeatability in the whole group of healthy volunteers
GROUP 1: within subject cortical perfusion coefficient of variation after 1-2 weeks — At day 7-14 Within subject coefficient of variation of measures computed by multiparametric renal MRI repeated after 1-2 weeks to assess cortical perfusion reproducibility in the whole group of healthy volunteers
GROUP 1: within subject cortical and medullary T1 coefficient of variation in few hour time — At day 0 Within subject coefficient of variation of measures computed by multiparametric renal MRI repeated in few hour time to assess cortical and medullary T1 repeatability in the whole group of healthy volunteers
GROUP 1: within subject cortical and medullary T1 coefficient of variation after 1-2 weeks — At day 7-14 Within subject coefficient of variation of measures computed by multiparametric renal MRI repeated after 1-2 weeks to assess cortical and medullary T1 reproducibility in the whole group of healthy volunteers
GROUP 1: within subject cortical and medullary T2 coefficient of variation in few hour time — At day 0 Within subject coefficient of variation of measures computed by multiparametric renal MRI repeated in few hour time to assess cortical and medullary T2 repeatability in the whole group of healthy volunteers
GROUP 1: within subject cortical and medullary T2 coefficient of variation after 1-2 weeks — At day 7-14 Within subject coefficient of variation of measures computed by multiparametric renal MRI repeated after 1-2 weeks to assess cortical and medullary T2 reproducibility in the whole group of healthy volunteers
GROUP 1: within subject cortical and medullary R2* coefficient of variation in few hour time — At day 0 Within subject coefficient of variation of measures computed by multiparametric renal MRI repeated in few hour time to assess cortical and medullary R2\* repeatability in the whole group of healthy volunteers
GROUP 1: within subject cortical and medullary R2* coefficient of variation after 1-2 weeks — At day 7-14 Within subject coefficient of variation of measures computed by multiparametric renal MRI repeated after 1-2 weeks to assess cortical and medullary R2\* reproducibility in the whole group of healthy volunteers
GROUP 1: within subject cortical and medullary ADC coefficient of variation in few hour time — At day 0 Within subject coefficient of variation of measures computed by multiparametric renal MRI repeated in few hour time to assess cortical and medullary ADC repeatability in the whole group of healthy volunteers
GROUP 1: within subject cortical and medullary ADC coefficient of variation after 1-2 weeks — At day 7-14 Within subject coefficient of variation of measures computed by multiparametric renal MRI repeated after 1-2 weeks to assess cortical and medullary ADC reproducibility in the whole group of healthy volunteers
GROUP 2 - Percentage of complete renal MRI data collection and analysis — At day 0 Percentage of complete renal MRI data acquired and generated by MRI data processing in the whole group of CKD patients, to assess feasibility of multiparametric renal MRI in CKD patients
Trial sites (4)
Facility
City
Region
Status
Aarhus University Hospital, Department of Renal Medicine
Århus N
Århus N
University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University
Heidelberg
Mannheim
Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"
Ranica
BG
Clínica Universidad de Navarra
Pamplona
Navarre
More Mario Negri Institute for Pharmacological Research trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.